GLP1R and cardiovascular disorder: For those at high risk for, or with pre-existing, cardiovascular disease, or with proteinuric kidney disease, there is now strong evidence for treatment escalation with sodium–glucose cotransporter 2 (SGLT2) inhibitors and/or glucagon-like peptide-1 receptor agonists (GLP-1RAs).